Recap: Affimed Q3 Earnings

Affimed (NASDAQ:AFMD) reported its Q3 earnings results on Tuesday, November 14, 2023 at 06:30 AM. Here’s what investors…

Affimed (NASDAQ:AFMD) reported its Q3 earnings results on Tuesday, November 14, 2023 at 06:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Affimed beat estimated earnings by 15.0%, reporting an EPS of $-0.17 versus an estimate of $-0.2.

Revenue was down $12.87 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.01 which was followed by a 1.56% increase in the share price the next day.

Here’s a look at Affimed’s past performance:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.21 -0.21 -0.21 -0.18
EPS Actual -0.22 -0.22 -0.22 -0.11
Revenue Estimate 4.53M 5.69M 7.95M 7.58M
Revenue Actual 1.51M 4.84M 11.39M 15.01M

To track all earnings releases for Affimed visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Scilex Holding Company Releases Preliminary Unaudited Financial Results For Gross And Net Sales For The Year Ended December 31, 2023; Total Product Gross Sales Were In The Range Of $150M-$155M; Total Product Net Sales Were In The Range Of $46.5M-$52.5M

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute

SCLX